Results 171 to 180 of about 1,390,389 (383)
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.
New England Journal of Medicine, 2017 F. C. Hamdy, J. Donovan, J. Lane, M. Mason, C. Metcalfe, P. Holding, M. Davis, T. Peters, E. Turner, Richard M. Martin, J. Oxley, M. Robinson, J. Staffurth, E. Walsh, P. Bollina, J. Catto, A. Doble, A. Doherty, D. Gillatt, R. Kockelbergh, H. Kynaston, A. Paul, P. Powell, S. Prescott, D. Rosario, E. Rowe, D. E. Neal, D. E. Neal +27 moresemanticscholar +1 more sourceBridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology
Molecular Oncology, EarlyView.Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme +8 morewiley +1 more sourceAdenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer
Molecular Oncology, EarlyView.A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.Magdalena Niemira, Anna Skwarska, Karolina Chwialkowska, Agnieszka Ostrowska, Gabriela Sokolowska, Anna Zeller, Anna Erol, Andrzej Eljaszewicz, Bartosz Hanczaruk, Anna Michalska‐Falkowska, Agnieszka Tarasik, Joanna Reszec‐Gielazyn, Pawel Knapp, Marcin Moniuszko, Adam Kretowski +14 morewiley +1 more sourceInvestigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer
Molecular Oncology, EarlyView.This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov +10 morewiley +1 more sourceCBCT-based online adaptive radiotherapy of the bladder – geometrical and dosimetrical considerations compared to conventional IGRT
Radiation OncologyBackground Bladder cancer radiotherapy presents unique challenges due to the dynamic anatomy of the bladder and the surrounding organs. Conventional image-guided radiotherapy (IGRT) relies on fixed treatment margins and daily couch corrections, which can Jann Fischer, Laura Anna Fischer, Jona Bensberg, Natalia Bojko, Mohamed Bouabdallaoui, Jasper Frohn, Petra Hüttenrauch, Mandy Klingebiel, Daniela Schmitt, Katharina Tegeler, Daniela Wagner, Alina Wenzel, Jessica Moldauer, Niklas Christian Scheele, Hanne Elisabeth Ammon, Stephanie Bendrich, Sandra Donath, Leif Hendrik Dröge, Manuel Guhlich, Andrea Hille, Olga Knaus, Martin Leu, Jan Oelmann, Rami El Shafie, Georg Stamm, Arndt F. Schilling, Stefan Rieken +26 moredoaj +1 more sourceBringing online adaptive radiotherapy to a standard C-arm linac
Physics and Imaging in Radiation OncologyCurrent online adaptive radiotherapy (oART) workflows require dedicated equipment. Our aim was to develop and implement an oART workflow for a C-arm linac which can be performed using standard clinically available tools.Maureen L. Groot Koerkamp, Gijsbert H. Bol, Petra S. Kroon, Lean L. Krikke, Tessa Harderwijk, Annelies J. Zoetelief, Annick Scheeren, Stefan van der Vegt, Annika Plat, Jochem Hes, Ineke B.A. van Gasteren, Esmee R.T. Renders, Reijer H.A. Rutgers, Saskia W. Kok, Joost van Kaam, Geja J. Schimmel-de Kogel, Gonda G. Sikkes, Dennis Winkel, Michael J. van Rijssel, André J.M. Wopereis, Kübra Ishakoglu, Juus L. Noteboom, Jochem R.N. van der Voort van Zyp, Naomi Beck, Timo F.W. Soeterik, Sandrine M.G. van de Pol, Wietse S.C. Eppinga, Corine A. van Es, Bas W. Raaymakers +28 moredoaj +1 more sourceThe influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients
Molecular Oncology, EarlyView.This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken +8 morewiley +1 more sourceEffects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
The Lancet, 2005 M. Clarke, R. Collins, S. Darby, C. Davies, P. Elphinstone, V. Evans, J. Godwin, R. Gray, C. Hicks, S. James, E. Mackinnon, P. McGale, T. McHugh, R. Peto, Carolyn Taylor, Yaochen Wang +15 moresemanticscholar +1 more sourceYAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma
Molecular Oncology, EarlyView.The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.Ant Murphy, Samuel Hartzler, Paula A. Vargas Carranza, Shyaman Jayasundara, Madison E. Yates, Nimod D. Janson, Bozhi Liu, Annaleigh Benton, Majid Kazemian, Jason A. Hanna +9 morewiley +1 more source